Disclosed is a composition for ameliorating, preventing or treating an autoimmune skin disease, containing a super pink (Dianthus superbus L.) extract as an active ingredient.

A medicinal, cosmetic or dermatologic product is described made from a reconstituted cannabis material. The reconstituted cannabis material forms a sheet-like layer that can be shape configured to cover a portion of a user's body. The product can be used as a face mask, as a wound dressing, or the like.

A traditional Chinese medicine composition includes 60%-80% by weight of Eucommia ulmoides extract, 15%-30% by weight of Rhizoma Drynariae extract and 5%-10% by weight of Semen Cuscutae extract. A method of preparing the traditional Chinese medicine composition is also provided. Uses of the traditional Chinese medicine composition in the prevention and/or treatment of osteoporosis are also provided.

Methods of removing contaminants such as pesticides, herbicides, and fungicides from plant-derived pharmaceuticals, such as cannabis-derived pharmaceuticals, are disclosed. Plant-derived pharmaceuticals, such as cannabis-derived pharmaceuticals, and methods of using the plant-derived pharmaceuticals are also disclosed.

The cosmetic use of one or more absolute(s) obtained from magnolia, juniper or violet for depigmenting the skin.

Disclosed is a composition for ameliorating, preventing or treating an autoimmune skin disease, containing a Musan box (Sphallerocarpus gracilis) extract or a fraction thereof as an active ingredient.

Novel thermal evaporative processes for the recovery of heat-sensitive constituents, raw essential oil concentrates, and other compounds from plant biomass material are disclosed, as are systems for implementing such processes. Particularly, the processes include a solvent-less process for either batch-wise or continuous removal and recover), of refined oils, such as volatile aroma components and heavier oils, from plant material.

This invention discloses nano-dimensional compositions of psychedelic drugs, entheogens, and medicinal mushrooms formed from lipids, polymers, stabilizers, mucoadhesives, permeation enhancers, and chemical stabilizers for delivering stable dosage forms by intraoral, gastrointestinal, transdermal, and intranasal, routes of administration. Disclosed are unified product extraction and manufacturing of stable nano-dimensional dosage forms of psychedelic drugs, entheogen, and medicinal mushrooms, and methods for improving their pharmacokinetics, pharmacodynamics, and efficacy. Also disclosed are methods for dephosphorylating the precursor psilocybin into active psilocin molecules, and fast-acting, nano-dimensional structures of psychedelic drugs taken by intranasal and intraoral routes of administration producing activity onset in less than 10 minutes.

Provided are a method of extracting saponin which is the physiologically active component of akebia quinata with high efficiency, by sequentially subjecting to a) adding akebia quinata flesh to akebia quinata seeds and performing aging; and b) extracting with alcohol, a method of further improving saponin extraction efficiency by adding ginger, and a food composition containing the extract produced by this method. Higher added value may be created by improving the saponin extraction efficiency from akebia quinata seeds using akebia quinata flesh which has not been utilized when extracting saponin.

A system for producing a blended extract of cannabinoids and terpenes, which extracts terpenes using supercritical CO2, and extracts a cannabinoid concentrate from the residual material using a cold ethanol flush followed by distillation; the CO2-extracted terpenes are then added back to the cannabinoid concentrate in a final blending step. Blending terpenes at the end of extraction may enhance the flavor and effectiveness of the cannabinoid concentrate. By separately extracting terpenes and cannabinoids, optimal processes and parameters may be used for each step. Blending may combine terpenes and cannabinoids in any desired ratio; for example, a terpene-to-cannabinoid ratio of approximately 1:10 may be used. The ethanol used in the cold ethanol extraction of cannabinoids may be recovered and reused for subsequent batches. Cannabinoid concentrates may be redistilled multiple times to enhance their concentration, followed by terpene blending.